and glaxo offered some good news the ceo said a couple things one, no geographic preferential treatment in terms of vaccine distribution clinical trials would begin soon in france and belgium and move on to the u.s., but merck is up 2% i want to turn you quickly to housing because toll did report, and you asked whether it's a counterurban trade, because we thought about toll in many ways in the last few years as an urban trade. >> i know, because they did all these fantastic projects we see them in new york. they ring new york city, and of course, they're in brooklyn and hoboken. toll was up $2 it was up $2 last night, and all on one figure. the figure was up 13% in may and that's really rather extraordinary. people feel that the rates are working. low rates. but this counterurban trade is

glaxo is the company that originally that originated this drug. they did studies they found some problems critics scientists say they really found more problems they should have reported they did and they're complaining that they didn't that they discarded a lot of the stomach contents in the tests and that's why they're saying that this is something that should have been caught a long time ago and there may have been some carelessness glaxo for their part said look we did what the f.d.a. wanted us to do we tested it in rodents and mice and there was no carcinogens found in the mice so look through argument both ways the to the matter is right now the f.d.a. is saying again stop taking it get rid of it all right rick sanchez host of the news with rick sanchez my friend and colleague great to see you thanks so much for that report. former new jersey governor chris christie seems to be in the clear from all charges related to bridge gate after the u.s. supreme court throws out the 2 convictions of 2 aides to the former governor and the aides were pr

glaxo smith kline which is british pfizer another u.s. company and xenophon french is just a small remainder of the market which is taken up by other firms of course we've also got the stops what i'd like to ask you is who has the best chance there i mean those big companies have a lot of money they have a lot of experience why on earth could a startup which is starting from scratch come up with something better. in the current crisis i don't believe that is that it's going to make the race i mean there that can help and there are already some start ups beginning clinical trials will call 1000 vaccine but on the other hand i do believe that in the current situation it's probably the best to begin with concepts that have already proven safety profiles and then at other technologies or let's say other entities other approaches to hunt about the accident after all and what startups are good at is being more radical redefining ways things are usually done in the past where some very good examples of that like for example back in the ninety's

then we have the old-timers, the glaxos which make your flu vaccine and other vaccines too that are goingied and true ways to try to do that, and that could take a bit longer. we're not really looking at a vaccine for at least a year or two. and is so it's going to make it a little harder for us as we try to reengage with the world. jack:j jack, why does it take so hong to develop a vaccine? >> i'm pretty far from being a there, but just think when you're making drugs, making treatments, you're giving those to sick people. when you're making vaccines, you're giving those to people who are well. the testing takes a long time. i would just say once we have a vaccine and we know it's safe, you might have noticed society is a little polarized when it comes to things like measles vaccines before. so we're not at the finish line yet once we have a vaccine. we still need to get enough people to take it. jack: al, how should investors be thinking about this? >> well, the funny thing with vaccines, it's tremendous for our economy, so you don't necessarily need -- [inaudible] however, vaccine is a

. >> reporter: the effort will be áheaded out by months of the áformer chief of vaccines glaxo smithby th áend of 2020. á>> reporter: nih director á doctor francis collins says átrouser on a fast track. á>> we would try to have 10 million doses of an effective ávaccine, or maybe a couple of ádifferent ones by october. á>> reporter:'s about the áexperts warned there are dangers áwithout promise. >> you cannot skip safety áabsolutely. ásafety is the most important thing.á á >> reporter: and epidemiology expert says vaccines typically takeá 12 to 18 months before á approval, for good reason. accordin áto the cdc, a new ávaccine must go through three áphases of clinical trials in áorder to get fda approval and áto test for safety and side effects.á is also the problem of how to manufature áand distribute vaccáines for the entire u.s. ápopulation of more than 300 millio americans.á á>> the logistics of distributing the vaccine are equall challenging.á á>> reporter: contra costa county health officer says ácounties will need to quickly áadd vaccine distribution site á to supplement regular

tell your children go to illegal but they go through your so what do you base your glaxo wellcome on sit down sit down could you please say sir down you get one why should. you do. this is the white health welcome to it this is where all of us it was being registered all the television people put the go the information that we provided a look. i work for c.n.n. it's an analyst of playboy i write a column. behind us you can see where everybody does their live shot all the major networks. that room used to be where we had briefings but we haven't had a briefing in about 2 months so instead what happens is there's a podium a makeshift podium you see people bringing chairs out here we have 249 chairs in air conditioning 50 feet away. no shit it's just joining this is sarah how do we sanders the press secretary is scheduled to come out here this morning to state run television fox and she'll probably come over and visit with us and hopefully have a few words to say to us and we'll try to find out some information places that place just. in the morning there are you do you think about aski

dwl glaxo is finally moving and if you want to know who is on the far turn is the glaxo/sanofi vaccine, which is very good. abbott, there's a story today about the new york -- the nyu hospital that says that their tests are unreliable i directly dispute that. they are doing things wrong, they're not doing the tests right. they're doing the time of transport is too long and they're doing the tests wrong. they're using viral transport medium -- forget the complaint it's wrong abbvie, can't wait to speak to them that combination is great. another steph name sensy, incredibly cheap. you cannot beat them in terms of medicare, medicaid for managed care united health. my hat is off to them. can they be better gilead, too much promote, not a lot of bad money coming down and it will be fine. >> hey, pete -- >> regeneron, by the way, is the one that have will the antibody. >> i don't know if cramer is looking to pick a fight with you, but costco, walmart, dollar general, home depot as his retail survivors, i don't see your minneapolis stock on that list >> it was on the -- >> it should be. it ha

monk left who is currently on board a swiss medical company former head of vaccine development at glaxo smith kline i think what people are really going to be interested in though are some of the comments by the u.s. president basically saying that regardless of whether or not a vaccine is found in the united states and his you have to get back to work and fight through it is the exact quote from the u.s. president believing that america will meet the moment the reality is the president knows that it's very unlikely there will be a vaccine by the end of the year in fact the estimates are 12 to 18 months best case scenario rarely is that a best case scenario so the prospect of there never being a vaccine is also a reality this country will have to deal with. as donald trump saying vaccine or no vaccine will be back what does that tell us about how important getting the economy back up and running is for this president and action here. it's critically important because this is a president that ran on creating jobs and had actually accomplished that until 8 weeks ago when all those jobs di

rival glaxo smith kline. the project could produce 600 million doses annually.nt is the importance of a vaccine. any development of a vaccine is needed to go back into to society with protections. there are dozens of countries seeking a vaccine right now. even today we sell president trump appointing leadership to his own manhattan project style effort to fast-track a. vaccine he named a former glaxo official t operationo w -- to operation warp speed. governments all over our in the race -- are in the race for a vaccine. haidi: to keita says it plans -- takeda plans a plasma based therapy as soon as july. its ceo is optimistic about the company's future. he spoke to bloomberg. >> a life-saving medicine. we are treating a very severe disease. treatment stop the for the disease. they are not linked to elective surgery. i think there will be some impact in some product, but overall we feel confident that, over time, our medicine will still be used by patients. >> unless i'm wrong, it seems like one of your main drugs is for crohn's disease, which is not life-threat

a chinese company and glaxo and sanofi which are partnered together >> you raised your price target to 90 on moderna some saying the vaccine experts are not happy with the amount of information moderna provided are you happy with what you've seen from moderna so far >> caller: the thing i focus on is that they have a core relation in the key pieces neutralizing antibodies, finding antibodies and the ability to elicit the andtibodies in a mous model. the numbers are small. the thing i'm looking for next is we'd expect the niaid that has partnered to public those results sometime before a phase three in july. that's when we'll get the details. >> then they would be able to scale it so everybody could get a dose by when, matthew. >> caller: they've said they could have a million doses in the fall tens of billions by the end of 2020 and tens of billions run rate by the end of 2021. >> matthew and his team doing incredible work. thank you for joining us in a first ever on cnbc interview you are working hard, we appreciate it. >>> that's it for us on a thursday dow futures down 150 oil is up

i'm not sure if there is something wrong with the mic karen, i remember the famous merger glaxo and smithklein. it was a megadeal. they promised to spend billions in r&d and really take this company all combined together and take it to the next level. then they didn't come up with that if you look at their share price today, they still haven't got back to that level they got back to at the end of december 1999 then comes to the unlocking of the genome and those exciting areas and the buy oiotec industa well a, they weren't making enough money. b, there were more anytime benie players around huge challenge for this industry it is a story we'll all talk about but we have to move on i'm standing outside waterloo station. mike and i have been around this morning and seen handfuls of people what is happening with the great return to work we'll discuss on "street signs." >>> welcome to "street signs." i'm karen tso, these are your headlines. the sharpest contraction since the financial crisis a warning the following period will be worse. >>> an industrial boost for european data showing the fir

. >> the former head glaxo smith kline to lead that effort alongside four-star army general gustav burnhamuse officials insist that yes, it is an aggressive timeline for the vaccine, it just a goal, not a certainty but they will give everything they have, jason. and also reopening the economy could well prove just as important as long-term health of the country, jason. >> jason: kevin, thank you. while the trump administration is doing everything it can to get america reopened quickly and safely, some of the left appeared toke be spreading fear about the push to reopen thehe country. i now that some governors have taken steps to loose l and stayt home orders, the media once again showing liberal bias. for example the governors of georgia and colorado have both taken similar steps to reopen their state. but brian kemp of georgia, a republican is -- they accused him of experimenting with "human sacrifice. despite the media's fearmongering, many americans have had enough with the forced lockdown. earlier today, hundreds of pennsylvanians gathered around the state capital to protest coronaviru

also working with glaxo-smith-kline are getting money. also in a race. it's really pretty good. a race. vaccines are tough. only about one in 100 eventually get approved and into our bodies. we need all these companies racing, including ones like moderna trying something new. >> that is a sobering statistic. the one in 100 you just said, drew. thank you very much for explaining what's happening on the front lines. we really appreciate that. >>> this might be a time when there is crying in baseball. the little league world series canceled because of the pandemic. we have details in the bleacher report, next. now more than ever, you need technology you can rely on. and people you can rely on. i'm a dell technologies advisor. me too. me too. me too. and if you're a small business, we're with you. we are with you. we're with you. we want to help. so we'll be right here. at home. answering your calls. providing support. and standing by you every step of the way. bye bye. won't be a new thing. and it won't be their first experience with social distancing. overcoming challenges is what

they don't, the stock is going to get eviscerated i'd rather have you in something that's diversified glaxo, pfizer, j & j same for biotech stocks. anything related to ebola, flu, except regeneron they have little in the way of profits or revenues which is why the stocks are very much at risk for one of these sell offs and they don't come back these stocks are way too hot if you own one of them, remember when the froth gets over the edge or ruins my ferragamo tie, it's time to quit. what else can't be touched the banks. did they look cheap? holy cow, people said do you want value it's the banks i know they have big yields, but this group got shelled today for a reason i want you to look at wells fargo. no, it will hurt your eyes maybe come with some visine or something. terrific c.e.o., charlie sharp the backing of warren buffett meaningful insider buy boun ti bountiful 90% yield. wrong! it's highly diversified. they don't make much money on the loans right now. they're looking at a lot more defaults ultra low rates means they can't make as much money on your deposits as the stock goes lowe

moncef slaoui has been working on vaccine development for over 17 years for glaxo smithkline beecham, which is that she's developed several vaccines in that position. and general perna actually is in charge of the army material command, and he was getting ready for retirement. he is in charge of over 200,000 employees, and does all the contracting for the military around the united states and around the world. these are two choices that will work together. what dod will do, department of defense, a lot of experience, given vaccines to military as you might imagine. but they also have -- they know how to deploy vaccines out around the world. out around the united states. in terms of vaccine development, harris, with the president says, they're switching candidates emerging. some of them are using new technology, genetic manipulation. the one out of england is using a little older technology, but it's already been tried in monkeys and looks successful there. several of these candidates have been tried in humans already, and i have shown a safety profile. the real end point here is, can

companies developing them include johnson & johnson, santa fe in conjunction with glaxo smith kline, is being tested on 45 patients. there may be early results late this month or in early june. finally, the indirect therapies. they do not directly treat the virus, but they help by mitigating some effects, such as difficulty with breathing or severe inflammation. roche is among the companies making these drugs. matt: for more, you can catch our special saturday. if you are in the u.k., unfortunately it is at 2:00 a.m. during the lockdown, the chances of you being awake at 2:00 a.m. are the same as the chances of you being awake at 2:00 p.m. if you are in the english speaking western world, you should not refer to the world health organization as the who, as that name that is reserved for the legendary rock band. w.h.o., orust say the w.h.o. or the world health organization. they are important, but not that important. gilead may spend $1 billion on its breakthrough new treatment for covid-19 this year alone. details from the u.s. government study in a separate trial conducted by the co

been two very competent scientists put in charge of this new initiative, a vaccine scientist out of glaxo. but, again, you're going to get this crunch that there's going to be a lot of pressure to get the vaccine out there before the election right around the time of the election, and the truth is, i don't see a path by which he can collect enough safety data and enough data that these vaccines work by then. i envision there could be some tensions yet again, because the phase three clinical trials for both efficacy and safety probably won't begin until the summer. the only agreement is, these vaccines will be ready by the fall the disagreement is, whether we're talking about the fall of 2020 or fall of 2021. i don't see a path by which it happens before fall of 2021. a source of friction i predict as well. >> one more question about vaccines, also pointed out, this is just startling, there's no path to do so with the adequate safety test for vaccine, we're talking about vaccinating the entire population, something that, i mean, most people are vaccinated. for the flu shot, everyone is obv

takeda is not working with a vaccine, but when you were at glaxo, you use to run the vaccine unit.ny thoughts about how you can ramp up a vaccine? , i thinke: first off we should be very clear that there's always the risk of lack , so i am convinced that a few will succeed, but not all of them. then the scalability of the manufacturing is a very complex endeavor. so -- [indiscernible] that will take time. so when we are talking about 2021, we are talking about in many cases the probability of the vaccines. it might take one or two years to scale up the manufacturing. alix: not news people want to hear, i am sure. take me inside what takeda is doing in terms of your workforce. have you made any sort of long-term shifts in how you structure the business, how you are hiring, what your medical centers look like, etc.? christophe: in early january, we to keep employees safe. , keeping oure manufacturing side running with alternative shifts. now it is how to regain some activity, but it will never be back as before because you need to keep the physical distancing. there is no way people